{
    "relation": [
        [
            "",
            "Part C: Dabrafenib 150 mg",
            "Part C: Dabrafenib 150 mg + Trametinib 1 mg",
            "Part C: Dabrafenib 150 mg + Trametinib 2 mg"
        ],
        [
            "Description",
            "Participants received dabrafenib 150 mg gelatin capsules BID.",
            "Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.",
            "Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD."
        ]
    ],
    "pageTitle": "Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212 - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT01072175?sect=Xh0156&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988311.72/warc/CC-MAIN-20150728002308-00248-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 868466855,
    "recordOffset": 868445778,
    "tableOrientation": "VERTICAL",
    "textBeforeTable": "Reporting Groups The study was comprised of Parts A, B, and D, which constitute the Phase I part of the study, and Part C, which constitutes the randomized Phase II part of the study. Participants did not enroll in all parts of the study sequentially. Each part of the study was comprised of a separate population of participants. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: GSK2118436 Drug: GSK1120212 Interventions: Cancer Condition: Allocation:\u00a0Non-Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Pharmacokinetics/Dynamics\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Open\u00a0Label; \u00a0",
    "textAfterTable": "Part B: Dabrafenib 150 mg + Trametinib 1.5 mg Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment. Part B: Dabrafenib 150 mg + Trametinib 2 mg Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi na\u00efve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib. Part C (Randomized): Dabrafenib 150 mg Participants received dabrafenib 150 mg gelatin capsules BID. Part C (Randomized): Dabrafenib 150 mg + Trametinib 1 mg Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD. Part C (Randomized): Dabrafenib 150 mg + Trametinib 2 mg Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}